We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
WELIREG (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
WELIREG
Date registered
Evaluation commenced
Decision date
Approval time
220 (255 working days)
Active ingredients
belzutifan
Registration type
EOI
Indication
WELIREG (belzutifan) is now also indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed cell death 1/ligand 1 (PD-1/L1) and a vascular endothelial growth factor (VEGF)-targeted therapy.